Notice2024-08986
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 26, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 82 (Friday, April 26, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 82 (Friday, April 26, 2024)]
[Notices]
[Page 32454]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-08986]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by contacting Dawn Taylor-Mulneix at
301-451-8021 or <a href="/cdn-cgi/l/email-protection#690d081e07471d081005061b44041c05070c001129070001470e061f"><span class="__cf_email__" data-cfemail="791d180e17570d180015160b54140c15171c100139171011571e160f">[email protected]</span></a>. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Human Monoclonal Antibodies That Target the RH5 Complex of Blood-Stage
Plasmodium Falciparum
Description of Technology
249 million people were afflicted with malaria in 2022. There are
five Plasmodium parasite species that cause malaria in humans. Of the
five, Plasmodium falciparum causes most of the incidence of human
disease. Most advanced malaria vaccine candidates can confer only
partial, short-term protection in malaria-endemic areas. The
pathogenesis of malaria is associated with blood-stage infection and
antibodies specific to the parasite blood-stage antigens may be able to
control parasitemia. To address this public health need, NIAID
inventors have developed 35 human monoclonal antibodies that target the
RH5 complex of blood-stage Plasmodium falciparum and were found to have
potent activity in in vitro growth inhibition assays.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Method of prophylactic and/or therapeutic treatment by
targeting blood-stage antigens of Plasmodium.
Competitive Advantages
<bullet> Most other commercially available antibodies targeting
against Plasmodium target circumsporozoite protein (CSP) present in the
sporozoite stage. These novel antibodies instead target a conserved and
essential antigen present in the blood stage: RH5.
<bullet> These monoclonal antibodies can be used alone or in
combination with existing antibodies.
Developmental Stage
<bullet> Pre-clinical.
Inventors: Joshua Tan, Ph.D., Lawrence Wang, Ph.D. and Andrew
Cooper, Ph.D., all of NIAID.
Publications: Wang, L., Cooper, A., et al. ``Natural malaria
infection elicits rare but potent neutralizing antibodies to the blood-
stage antigen RH5.'' bioRxiv. <a href="https://www.biorxiv.org/content/10.1101/2023.10.04.560669v1">https://www.biorxiv.org/content/10.1101/2023.10.04.560669v1</a>, October 06, 2023.
Intellectual Property: HHS Reference No. E-014-2023; Provisional
Patent Application No.: 63/468,740.
Licensing Contact: To license this technology, please contact Dawn
Taylor-Mulneix at 301-451-8021 or <a href="/cdn-cgi/l/email-protection#e28683958ccc96839b8e8d90cf8f978e8c878b9aa28c8b8acc858d94"><span class="__cf_email__" data-cfemail="046065736a2a70657d686b76296971686a616d7c446a6d6c2a636b72">[email protected]</span></a>, and
reference E-014-2023.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Dawn Taylor-Mulneix at 301-451-8021 or
<a href="/cdn-cgi/l/email-protection#e783869089c993869e8b8895ca8a928b89828e9fa7898e8fc9808891"><span class="__cf_email__" data-cfemail="a9cdc8dec787ddc8d0c5c6db84c4dcc5c7ccc0d1e9c7c0c187cec6df">[email protected]</span></a>.
Dated: April 19, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-08986 Filed 4-25-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 26, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.